Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: A report from the European Osteosarcoma Intergroup

[1]  S. Strauss,et al.  Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma , 2012, Cancer.

[2]  D. Eslin,et al.  Prognostic significance of early lymphocyte recovery in pediatric osteosarcoma , 2010, Pediatric blood & cancer.

[3]  J. Blay,et al.  Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. , 2009, Cancer research.

[4]  M. Sydes,et al.  International collaboration is feasible in trials for rare conditions: the EURAMOS experience. , 2007, Cancer treatment and research.

[5]  T. Yamanaka,et al.  Predictive value of chemotherapy-induced neutropenia for the efficacy of oral fluoropyrimidine S-1 in advanced gastric carcinoma , 2007, British Journal of Cancer.

[6]  M. van Glabbeke,et al.  Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. , 2007, Journal of the National Cancer Institute.

[7]  E. Kleinerman,et al.  Early Lymphocyte Recovery as a Prognostic Indicator for High-risk Ewing Sarcoma , 2007, Journal of pediatric hematology/oncology.

[8]  U. Banerji,et al.  The association of chemotherapy induced neutropenia on treatment outcomes in small cell lung cancer. , 2006, Lung cancer.

[9]  P. Picci,et al.  No correlation between methotrexate serum level and histologic response in the pre-operative treatment of extremity osteosarcoma , 2006, Anti-cancer drugs.

[10]  Piero Picci,et al.  Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy , 2006, Cancer.

[11]  M. Tan,et al.  High‐dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma , 2004, Cancer.

[12]  E. van Marck,et al.  Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup. , 2002, European journal of cancer.

[13]  W. Winkelmann,et al.  Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  D. Machin,et al.  Received dose and dose-intensity of chemotherapy and outcome in nonmetastatic extremity osteosarcoma. European Osteosarcoma Intergroup. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  C. Blomqvist,et al.  Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF , 1999, British Journal of Cancer.

[16]  S. Ferrari,et al.  Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  R. Souhami,et al.  Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup , 1997, The Lancet.

[18]  Yin Bun Cheung,et al.  Survival Analysis: A Practical Approach , 1995 .

[19]  U. Bode,et al.  Methotrexate pharmacokinetics and prognosis in osteosarcoma. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  A. Davis,et al.  Prognostic factors in osteosarcoma: a critical review. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  A. Craft,et al.  A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  D. Cruickshank,et al.  A randomised study comparing standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancer. , 1992, British Journal of Cancer.

[23]  R. Reznick,et al.  Survival analysis: A practical approach , 1989, Diseases of the colon and rectum.

[24]  S. Richards,et al.  Prognostic importance of myelosuppression during maintenance treatment of lymphoblastic leukaemia. Leukaemia in Childhood Working Party of the Medical Research Council. , 1989, Archives of disease in childhood.

[25]  K. Schmiegelow,et al.  White cell count during maintenance chemotherapy for standard-risk childhood acute lymphoblastic leukemia: relation to relapse rate. , 1988, Pediatric hematology and oncology.

[26]  R. D. Hunter,et al.  WHO Handbook for Reporting Results of Cancer Treatment , 1980 .